New mechanism for release of endosomal contents:
osmotic lysis via nigericin-mediated K/H exchange

Loganathan Rangasamy, Venkatesh Chelvam, Ananda Kumar Kanduluru, Madduri Srinivasarao,
Achini N Bandara, Fei You, Esteban Orellana, Andrea L Kasinski, and Philip S. Low

Bioconjugate Chem., Just Accepted Manuscript • DOI: 10.1021/acs.bioconjchem.7b00714 • Publication Date (Web): 15 Feb 2018

Downloaded from http://pubs.acs.org on March 1, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Ionophore-mediated endosomal release

83x49mm (300 x 300 DPI)
New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K\(^+\)/H\(^+\) exchange

Loganathan Rangasamy\(^1\), Chelvam Venkatesh\(^{1,2}\), Ananda Kumar Kanduluru\(^1\), Madduri Srinivasarao\(^1\), Achini Bandara\(^3\), Fei You\(^3\), Esteban A. Orellana\(^4\), Andrea L. Kasinski\(^4\) and Philip S. Low\(^1\)*

\(^1\)Purdue Institute for Drug Discovery, 720 Clinic Drive, West Lafayette 47907, USA. * Corresponding author. E-mail: plow@purdue.edu; Phone: 765-494-5272; Fax: 765-494-0239.  
\(^2\)Discipline of Chemistry, Centre for Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh, India.  
\(^3\)Endocyte, Inc., 3000 Kent Ave., Suite A1-100, West Lafayette, IN, 47906, USA.  
\(^4\)Department of Biological Sciences, Bindley Bioscience Center, Purdue University, West Lafayette, USA.

Abstract

Although peptides, antibodies/antibody fragments, siRNAs, antisense DNAs, enzymes and aptamers are all under development as possible therapeutic agents, the breadth of their applications has been severely compromised by their inability to reach intracellular targets. Thus, while macromolecules can often enter cells by receptor-mediated endocytosis, their missions frequently fail due to an inability to escape their entrapping endosomes. In this paper, we describe a general method for promoting release of any biologic material from any entrapping endosome. The strategy relies on the fact that all nascent endosomes contain extracellular (Na\(^+\)-enriched) medium, but are surrounded by intracellular (K\(^+\)-enriched) fluid in the cytoplasm. Osmotic swelling and rupture of endosomes will therefore be facilitated if the flow of K\(^+\) down its concentration gradient from the cytosol into the endosome can be facilitated without allowing downhill flow of Na\(^+\) from the endosome into the cytosol. While any K\(^+\) selective ionophore can promote the K\(^+\) specific influx, the ideal K\(^+\) ionophore will also exchange influxed K\(^+\) for an osmotically inactive proton (H\(^+\)) in order to prevent buildup of an electrical potential that would rapidly halt K\(^+\) influx. The only ionophore that catalyzes this exchange of K\(^+\) for H\(^+\) efficiently is nigericin. We demonstrate here that ligand-targeted delivery of nigericin into endosomes that contain an otherwise impermeable fluorescent dye can augment release of the dye into the cell cytosol via swelling/bursting of the entrapping endosomes. We further show that nigericin-facilitated escape of a folate-targeted luciferase siRNA conjugate from its entrapping endosomes
promotes rapid suppression of the intended luciferase reporter gene. Taken together, we propose that ionophore-catalyzed entry of $K^+$ into endosomal compartments can promote release of otherwise impermeable contents from their encapsulating endosomes.

**Introduction**

Although the majority of prescription drugs today are small organic molecules, their share of the pharmaceutical market is declining in favor of biological macromolecules which now comprise ~39% of drugs in the pharmaceutical pipeline.\(^1\) This shift towards biologics has been driven by both the diversity of biologic molecules that can be exploited for pharmacologic applications (e.g. oligonucleotides,\(^2\) genes,\(^3\) proteins,\(^4,5\) peptides,\(^6\) carbohydrates,\(^7,8\) immune conjugates,\(^9-11\) synthetic biopolymers,\(^12\) etc.) and the increased numbers of diseases for which biologic therapies seem well suited.\(^13-17\) Unfortunately, a major constraint still limiting the use of biologics is their inability to cross membranes, thereby confining their sites of action largely to extracellular spaces. Thus, the predominant targets of biologics today still constitute cell surface antigens,\(^18\) secreted cytokines,\(^18\) transmembrane receptors,\(^19\) cell adhesion molecules,\(^20\) and extracellular matrix proteins;\(^21,22\) i.e., leaving the desirable intracellular signaling complexes, transcription factors, enzymatic pathways, structural assemblies, coding and noncoding RNAs, and chromatin remodeling components largely unaddressed.\(^23\)

Although membrane barriers that restrict most biologics to extracellular spaces may differ somewhat among classes of macromolecular drugs, the most commonly encountered barrier lies in crossing the endosomal membrane. Thus, with the aid of a receptor-binding ligand, most macromolecules can be delivered via receptor-mediated endocytosis into an intracellular compartment. However, escape from that intracellular compartment into the cytoplasm is usually a low probability event. For example, during pinocytosis extracellular solutes can become entrapped within tiny (100 nm diameter) membrane invaginations that pinch off and traffic through intracellular endosomes, however, the internalized macromolecules rarely escape their entrapping compartments at any site along this pathway.\(^24\) Similarly, during macropinocytosis much larger quantities of extracellular medium can become engulfed by a different internalization mechanism,\(^25\) but again release of the encapsulated macromolecules into the
cytoplasm is very inefficient. While receptor-mediated endocytosis concentrates bound ligands (and any attached cargoes) onto cell surface receptors before transporting them into cells via membrane invagination,\textsuperscript{26,27} the intracellular fates of such internalized biologics is again essentially the same: i.e. stable entrapment within an endosome.\textsuperscript{23} Thus, regardless of the internalization pathway, escape of biologics from their encapsulating endosomes constitutes a limiting step in use of biologics to treat diseases originating within a cell.\textsuperscript{23}

Because endosomal release has long been recognized as the primary barrier to broader use of biologic therapeutics, considerable effort has been devoted to finding strategies for release of biologic components. While most such strategies show some degree of success \textit{in vitro}, all have limitations that prevent their translation into clinical practice.\textsuperscript{28} For example, cationic lipids and peptides are not only often toxic, but they may also bind nonspecifically to cell surfaces, thereby compromising potential applications in targeted drug delivery.\textsuperscript{29} While “proton sponges” can induce counterion uptake and the consequent osmotic swelling of entrapping endosomes, they are also frequently toxic and the amount of material required to promote endosome lysis can also be clinically impractical.\textsuperscript{30} And although pore-forming peptides can mediate escape of small molecules from intracellular compartments, their small pore sizes almost invariably prevent their use for delivery of larger biologics.\textsuperscript{28} Finally, despite the established ability of certain photoactivatable dyes to induce endosomal lysis, use of such photolytic agents requires illumination of the targeted cell with a light source, greatly restricting its applicability to tissues that can be irradiated with light.\textsuperscript{31-33} Taken together, an efficient method for facilitating release of biologics from entrapping endosomes is still lacking, and any new approach that might improve biologic delivery justifies further scrutiny. The strategy below has the potential to achieve this objective.
Figure 1. Release of biologics from endosomal compartments using a $K^+/H^+$ ionophore to promote osmotic lysis of the endosomes. Endocytosis of a biologic into a target cell occurs by membrane invagination and budding as shown in the upper left corner. The lumen of the nascent early endosome will contain extracellular fluid characterized by high $Na^+$ concentration (orange spheres), while the cytosol surrounding the internalized endosome contains the usual high intracellular $K^+$ concentration (green spheres; left endosome). Co-delivery of nigericin, an ionophore that transports $K^+$ in exchange for $H^+$, with a desired biologic into the endosome can then allow the electroneutral influx of $K^+$ in exchange for an efflux of $H^+$. Because $K^+$ is osmotically active while $H^+$ is not, this exchange results in endosome swelling and eventual lysis, releasing the biologic into the cell’s cytosol. In the studies described below, nigericin is delivered together with a model biologic into the endosome by folate receptor-mediated endocytosis.

Summary of Strategy In theory, any mechanism that can enhance the unidirectional entry of an osmotic solute into an endosome must promote the osmotic swelling of that endosome. In considering possible strategies that might induce this unidirectional flux of ions into an endosome, we realized that the endocytic process actually establishes the osmotic conditions that can facilitate such influx. Thus, any mammalian plasma membrane that invaginates and pinches off inside a cell will entrap a $Na^+$ rich extracellular fluid within the endosome and exclude a $K^+$ rich intracellular fluid that comprises the cytosol (Fig. 1); i.e. setting up both $K^+$ and $Na^+$ gradients across the endosomal membrane.\textsuperscript{34,35} Thus, any ionophore that can selectively
transport $K^+$ down its concentration gradient (i.e. into the endosome) without simultaneously allowing $Na^+$ to flow down its concentration gradient out of the endosome must increase the osmotic pressure within the endosome. As diagrammed in Fig. 1, such increase in osmotic pressure within the endosome must force an influx of water that will swell the endosome. Moreover, analysis of the Nernst equation reveals that this endosome swelling will continue until either: i) the endosome bursts due to the rising osmotic pressure, or ii) the rising electrochemical potential of $K^+$ across the endosomal membrane (i.e. due to buildup of intraluminal $K^+$ and its positive charge) reaches equilibrium, i.e. preventing further influx of $K^+$. Therefore, in order to enable $K^+$ to continuously enter the endosome unimpeded by a rising electrical potential, it seemed prudent to find a way to allow a positive charge to leave the endosome without pulling any water with it. Since the only positively charged particle that is not osmotically active is the proton ($H^+$), this additional condition requires that we employ an ionophore that will exchange $K^+$ (but not $Na^+$) for $H^+$ (but not any other cation). Fortunately, nature has provided such an ionophore in the form of nigericin 1 (Fig. 2A), which facilitates the electroneutral entry of an osmotically active $K^+$ in exchange for an osmotically inactive $H^+$, thereby promoting the osmotic swelling of an endosome unhindered by any build-up of membrane potential.$^{36}$

In this paper we describe the use of nigericin to promote the osmotic lysis of endosomes and the consequent release of otherwise membrane-impermeable biologics from their entrapping intracellular compartments. We first show that a folate-rhodamine conjugate containing a membrane-impermeable rhodamine dye can enter endosomes via folate receptor-mediated endocytosis and be released from otherwise impermeable endosomes upon nigericin-mediated endosome swelling and bursting. We then demonstrate that siRNA-mediated knockdown of a luciferase reporter gene can be significantly enhanced when nigericin is co-delivered with the folate-targeted siRNA. Taken together with the fact that nigericin is nontoxic to cells up to concentrations $>100$ nM (supplemental Figs. S1B and S2),$^{37,38}$ these data suggest that nigericin-mediated swelling of endosomal compartments can facilitate release of biologics from entrapping endosomes without causing significant toxicity to the targeted cell.
Results
To conduct an initial test of the concept proposed in Fig. 1, we first investigated whether nigericin 1 (Fig. 2A) could promote osmotic bursting of unilamellar calcein-containing liposomes that had been assembled with high intraluminal Na\(^+\) and high extraluminal K\(^+\); i.e. similar to the ion gradients surrounding endosomes in living cells. For this and subsequent purposes, we prepared the folate-nigericin conjugate 2 (Fig. 2A) by esterification of nigericin’s free carboxylic acid to a hydrophilic peptide spacer that was in turn conjugated to folic acid for use in targeting folate receptor (FR) expressing cells. Because endosomal compartments are reducing in nature,\(^3\) the design of the folate nigericin conjugate included a self-immolative disulfide linker\(^4\) that is rapidly cleaved upon disulfide reduction, thereby releasing free nigericin into the entrapping endosome. As seen in Fig. 2B, escape of the membrane-impermeable dye, calcein, from the synthetic unilamellar liposomes was maximal when the vesicles were quantitatively lysed with detergent (Triton X-100) (positive control). In contrast, release of the impermeable calcein was minimal when only buffer plus DMSO were added (negative control). Importantly, when the vesicle suspension was exposed to either free nigericin 1 or folate-nigericin conjugate (ester 2, 100 nM) in the presence of 20 mM dithiothreitol (to promote disulfide bond reduction and nigericin release), nearly maximal escape of calcein was again observed (Fig. 2B). Evidence that this calcein release was dependent on a Na\(^+\)/K\(^+\) gradient across the liposomal membrane was established by demonstrating a lack of calcein release when the intraliposomal Na\(^+\) was exchanged for the same concentration of liposomal K\(^+\) (i.e. the electrochemical gradient was collapsed). Taken together, these data demonstrate that nigericin can mediate the bursting of a membrane-encapsulating compartment if the compartment is constructed with a Na\(^+\)/K\(^+\) transmembrane gradient similar to that seen in endosomes.
Figure 2. Nigericin-mediated release of a membrane-impermeable calcein dye from unilamellar phospholipid vesicles. A) Structure of nigericin, 1 and folate-nigericin conjugates, 2 and 3. B) Bar graph quantitating the release of calcein from synthetic unilamellar vesicles prepared in 20 mM potassium phosphate buffer pH 7.0 containing 130 mM intralumenal NaCl and 130 mM extralumenal KCl, followed by incubation for 4 h in: i) 1.5% Triton X-100 (detergent) to release all intravesicular calcein; ii) 0.1% DMSO in 130 mM KCl/20 mM K$_3$PO$_4$ buffer; iii) 100 nM nigericin 1 dissolved in the same DMSO-containing buffer; iv) 100 nM folate-nigericin ester conjugate 2 dissolved in the same buffer containing 20 mM dithiothreitol (DTT) to reduce the disulfide bond. As a second negative control, analogous liposomes were prepared
with no Na\(^+\) or K\(^+\) gradient across their membranes (i.e. 130 mM KCl both inside and outside the liposome), and then treated with 100 nM folate-nigericin ester conjugate 2 dissolved in the same buffer containing 20 mM dithiothreitol (DTT) to reduce the disulfide bridge.

To determine whether nigericin might promote similar bursting of intracellular endosomes in living cells, we next treated FR-positive KB cells with a folate-rhodamine conjugate 4 (Fig. 3A) that readily enters FR-expressing cells via folate receptor-mediated endocytosis.\(^3\) Although the folate-rhodamine conjugate was designed to release free rhodamine following its endocytosis (due to reduction of its disulfide bond in intracellular endosomes), the discharged rhodamine is known to remain entrapped within the endosome due to its strong positive and negative charges.\(^4\) To evaluate whether nigericin might enable release of this entrapped rhodamine, 10 nM folate-rhodamine was added to FR-positive KB cells, both in the presence and absence of 100 nM folate-nigericin ester 2. Because many FR are known to internalize into the same FR-positive endosome,\(^4\) it was anticipated that multiple copies of both conjugates 2 and 4 would be internalized into each endosome, allowing the released nigericin to catalyze the escape of the rhodamine entrapped within the same endosome.

As shown in Fig. 3B, the aforementioned predictions were only partially realized. As anticipated, within 1 h of conjugate 2 addition, rhodamine containing endosomes were seen to swell only in those cells treated with both folate-rhodamine plus folate-nigericin 2, but not in cells treated solely with folate-rhodamine. These data suggested that folate-nigericin 2 was indeed required for endosome swelling. By 2 h post-administration, however, many of the nigericin-containing endosomes had continued to enlarge, expanding eventually to many times the size of folate-rhodamine containing endosomes in cells not treated with folate-nigericin, but surprisingly without bursting. Indeed, only a fraction of the swollen endosomes displayed plumes of escaping free rhodamine emerging from their surfaces (see green arrow, Fig. 3B). Although by 3 h post-administration a greater fraction of the swollen endosomes showed plumes of released rhodamine (along with diffuse rhodamine staining within the cytoplasm), the majority of rhodamine fluorescence appeared to remain encapsulated within the greatly enlarged endosomes. Because endosomes in cells treated solely with folate-rhodamine 4 remained relatively unchanged except for the slow migration of the fluorescent endosomes towards the cell’s interior, we conclude that enlargement and periodic rupture of endosomes requires the
involvement of folate-nigericin. Whether the unanticipated continual endosome expansion occurs because the initial endosomes are part of an elaborate anastomosing network of intracellular compartments that share a common encapsulating membrane, or because the swelling endosomes are induced to rapidly fuse to increase their surface to volume ratios cannot be ascertained from the data. However, the fact that some release of contents occurs during swelling motivated us to explore this endosome escape strategy further.
A

Folate-rhodamine Conjugate 4

B

<table>
<thead>
<tr>
<th>Folate-rhodamine (10 nM)</th>
<th>Folate-rhodamine (10 nM) + Folate-nigericin 2 (100 nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>![Image 1]</td>
<td>![Image 2]</td>
</tr>
<tr>
<td>![Image 3]</td>
<td>![Image 4]</td>
</tr>
<tr>
<td>![Image 5]</td>
<td>![Image 6]</td>
</tr>
<tr>
<td>![Image 7]</td>
<td>![Image 8]</td>
</tr>
<tr>
<td>![Image 9]</td>
<td>![Image 10]</td>
</tr>
</tbody>
</table>

ACS Paragon Plus Environment
Figure 3. **Nigericin-mediated release of rhodamine entrapped in KB cell endosomes following folate receptor-mediated endocytosis.** A) Structure of the folate-rhodamine conjugate 4 B) Confocal fluorescence microscopy images of KB cells at 1 h (top), 2h (middle), and 3h (bottom) following treatment with 10 nM folate-rhodamine conjugate 4 either in the absence (left panels) or presence (right panels) of 100 nM folate-nigericin conjugate 2. The green arrow at 2 h (middle panels) shows an example of the “pluming” phenomenon that we associate with escape of the dye from an entrapping endosome. By 3 h post-treatment, some of the swollen endosomes had merged into much larger compartments such as the one shown in the lower right hand panel.

To determine whether nigericin-mediated endosome swelling might be exploited to deliver a larger folate-targeted biologic into a cell’s cytosol, we next constructed the folate-siRNA conjugate 5 shown in Fig. 4A, where the targeting ligand (folate) was conjugated to the 3’ end of one strand of a duplex siRNA, while a fluorescent dye (Dylight 647; (Dy647)) was linked to the 3’ end of the complementary strand (Fig. 4A). Based on this design, Dylight 647 binding and endocytosis should only be seen in fluorescence micrographs of treated cells when the intact siRNA duplex is delivered into the cell. As shown in Fig. 4B, few differences can be observed between folate-nigericin 2 treated and untreated cells during the first 3 h of incubation. However, by 5 h post-administration, significant swelling, aggregation and pluming of fluorescence can be seen from endosomes in the folate-nigericin 2 treated samples, but not in control cells. Although these data suggest that endosome swelling and leakage may require more time to release the larger folate-siRNA conjugate, the end result appears to be the same, with endosome swelling and release of Dy647-siRNA (see green arrows in Fig. 4B) also occurring when the biologic is larger.
Figure 4. Nigericin-mediated release of folate-Dy647-siRNA conjugate 5 from endosomes. A) Structure of folate-Dy647-siRNA 5. B) Confocal fluorescence microscopy images showing the release of Dy647-labeled folate-siRNA (400 nM) from endosomes of KB cells in the absence (left
panels) and presence (right panels) of folate-nigericin conjugate 2. The green arrows suggest “pluming” of contents as they stream away from the endosome.

Although nigericin is not highly toxic to mammals (LD$_{50}$ in mice is only 190 mg/kg),$^{43}$ it was still important to minimize any premature release of ionophore that might occur during transit within the bloodstream to the target cell. For this purpose, we explored whether a more stable carbamate linkage to nigericin (Fig. 5A, conjugate 6) might prove equally potent in promoting endosome swelling. As shown in Fig. 5B, endosome swelling and release was equally effective with the carbamate conjugate 6 as with the ester conjugate 2 (100 nM). Thus, not only was significant endosome enlargement/aggregation also apparent, but the usual plumes of released dye could even be seen inside the cells as early as 1 h after exposure (Fig. 5B). These data suggest that use of the more stable carbamate linker does not compromise nigericin’s ability to promote endosome bursting.
Figure 5. Endosome release of folate-rhodamine 4 using carbamate functionalized folate-nigericin conjugate 6. A) Structure of folate-nigericin carbamate 6. B) Chronology of endosome swelling and folate-rhodamine escape over the first four hours is shown for KB cells treated with 10 nM folate rhodamine conjugate 4 and 90 nM folate-nigericin carbamate conjugate 6.

To further minimize any possible nigericin-mediated toxicity, we next explored whether lower concentrations of folate-nigericin might induce similar endosome swelling and rupture. As shown in Fig.6A, 60 nM folate-nigericin carbamate conjugate 6 still promoted endosome
enlargement and rhodamine release (see Fig. 5B). Curiously, 30 nM folate-nigericin carbamate conjugate 6 was also effective at inducing endosome enlargement and rhodamine release (Fig. 6B). In contrast, still lower concentrations of folate-nigericin showed increasingly weaker potency (data not shown), suggesting that concentrations of targeted nigericin below 30 nM might not be adequate for catalysis of endosome swelling and rupture.

**Figure 6. Effect of lower concentrations of folate-nigericin carbamate 6 on escape of folate-rhodamine conjugate 4 from encapsulating endosomes.** Endosome escape of 10 nM folate-rhodamine conjugate 4 from KB cells upon co-administration of either 60 nM (A) or 30 nM (B) of folate-nigericin carbamate conjugate 6 at the indicated times. Green arrows indicate examples of the pluming of endosomal contents.

To explore the generality of nigericin-mediated endosome swelling, we elected to examine whether folate-targeted nigericin might facilitate endosome enlargement and leakage in two other unrelated cell types. First, since all of the above experiments were conducted on a nasopharyngeal cancer cell line (KB cells), we next conducted analogous studies on a triple negative breast cancer cell line (MDA-MB-231). As shown in Fig. 7A, endosomal escape was
again only observed in cells treated with a folate-nigericin conjugate, with pluming of rhodamine fluorescence appearing more frequently in cultures treated with the folate-nigericin amide than its ester counterpart. In fact, except for a somewhat delayed progression of the swelling/bursting process in MDA-MB-231 cells, the response of the cells to co-delivery of nigericin was similar to that seen in KB cells.

Next, to explore whether a still more unrelated cell type might display a similar response to co-internalization of nigericin, we again conducted identical studies on RAW 264.7 cells, a malignant macrophage cell line that differs from KB cells not only in its cell of origin, but also in its targeted receptor (i.e. RAW264.7 cells express the beta form of the folate receptor rather than the alpha isoform present on KB and MDA-MB-231 cells). As displayed in Fig. 7B, co-delivery of nigericin into RAW264.7 endosomes promoted both endosome swelling and rhodamine release in a similar but less prominent manner than seen in KB cells. And again, these perturbations were completely absent in cells not treated with folate-nigericin.
A

<table>
<thead>
<tr>
<th>Folate-rhodamine (10 nM)</th>
<th>Folate-rhodamine (10 nM) + Folate-nigericin ester 2 (100 nM)</th>
<th>Folate-rhodamine (10 nM) + Folate-nigericin amide 3 (100 nM)</th>
</tr>
</thead>
</table>

2 h

4.5 h

7 h
Figure 7. Nigericin-mediated escape of rhodamine from endosomes in FRα-expressing MDA-MB-231 cells and FRβ-expressing RAW264.7 cells. A) MDA-MB-231 cells were treated with 10 nM folate-rhodamine and 100 nM folate-nigericin.
nM folate rhodamine conjugate 4 in the absence (left panels) or presence of 100 nM folate-nigericin ester conjugate 2 (middle panels) or 100 nM folate-nigericin amide conjugate 3 (right panels). The green arrows identify sites of “pluming” of contents as entrapped rhodamine streams away from the endosome.  B) Nigericin-mediated escape of rhodamine from endosomes in FRβ-expressing RAW264.7 cells. Cells were treated with 10 nM folate rhodamine conjugate 4 in the absence (left panels) or presence (right panels) of 100 nM folate-nigericin ester conjugate 2.

Finally, to confirm that the apparent nigericin-mediated swelling and leakage of endosomal contents can deliver a functional biologic into a target cell, the ability of a folate-conjugated antisense oligonucleotide (siLuc2) to suppress luciferase 2 gene expression was examined. For this purpose, MDA-MB-231 cells were stably transfected to constitutively express luciferase 2 and then incubated with a folate-siLuc2 antisense conjugate either lacking (structure 7) or containing at attached nigericin (structure 8). As shown in Fig. 8C, no difference in luciferase activity could be detected between the two constructs for the first 18 h of incubation (perhaps due to the large number of pre-existing copies of luciferase enzyme in the cells). However, at later time points a significant difference in luciferase activity was observed, with little reduction seen in cultures exposed to the folate-siRNA lacking nigericin, but a significant decrease seen in cultures treated with the conjugate containing nigericin (see Fig. S14 in Supporting Information for more controls). The reduced potency of luciferase gene suppression by the construct lacking nigericin strongly argues that endosome swelling and leakage can be facilitated by co-delivery of nigericin into the endosomes.
Figure 8. Nigericin-mediated release of Folate-conjugated siLuc2. A) Structures of Fol-siLuc2 or Fol-nigericin-siLuc2 conjugate. B) Luciferase2 enzyme activity in MDA-MB-231 cells as a function of time after treatment with either folate-siLuc2 or folate-nigericin-siLuc2 conjugate. Luciferase activity levels were normalized to a negative control (a scrambled siRNA). Mean ± S.D., technical replicates= 3, n=3, * P<0.05. The arrow indicates replacement of media with a new dose of folate conjugates (50 nM). Fol-SiLuc2: Folate-siLuc2; Fol-Nig-SiLuc2 conjugate: Folate-nigericin-siLuc2 conjugate. The gene-knockdown experiment indicated a rapid reduction in luciferase activity in Fol-nigericin-siLuc2 treated cells as soon as 18 hours post treatment and reaches 30-35% after 24 h.
Discussion

The folate receptor is a membrane-anchored protein that is rarely expressed on healthy cells but over-expressed on ~ 40% of human cancer cells, including malignant cells from lung, breast, ovarian, colon and kidney cancers. Not surprisingly, FRα has been frequently exploited for receptor-mediated delivery of folate-linked membrane-permeable drugs into cancer cells, since escape of membrane-permeable drugs from entrapping endosomes proceeds by passive diffusion. In contrast, the ability of membrane-impermeable drugs to escape entrapping endosomes has been disappointing to date, with most biologic drugs never accessing their targets in the cytoplasm. Because nearly all receptor-mediated delivery pathways suffer from this same limitation, targeted delivery of biologics into pathologic cells will not likely be possible until a clinically useful endosome escape mechanism can be developed. To test the ability of nigericin to mediate osmotic lysis of endosomes, we constructed multiple membrane-impermeable folate conjugates that could only enter a cell’s cytosol if its internalizing endosomes were ruptured. Using this system we were able to demonstrate that ester-, amide- and carbamate-bridged folate-nigericin conjugates could all successfully promote release of otherwise impermeable folate-rhodamine and folate-siRNA conjugates from intracellular endosomes in KB, MDA-MB-231 and RAW274.7 cells. Taken together, we conclude that co-delivery of nigericin into entrapping endosomes can mediate osmotic swelling and at least partial lysis of endosomes, allowing escape of entrapped contents into a target cell’s cytoplasm.

Why might a nigericin-mediated endosome lysis strategy be preferred over other endosome release mechanisms? From our perspective, use of nigericin may primarily be favored because of its ease of translation into the clinic. Thus, nigericin is a small, stable, well-characterized, nontoxic, and easily conjugatable organic molecule that can be attached via a variety of self-immolative linkers to virtually any biologic molecule destined for clinical use. Because the resulting conjugate can be prepared in a homogeneous formulation that can be molecularly characterized by FDA-approved methods, its stability and manufacturing reproducibility should be readily documentable. Moreover, by avoiding problems with toxicity, homogeneity and efficacy that can plague cell permeating peptides, polycations, pore-forming peptides, and proton sponges, many of the pitfalls that limit utility of other endosome escape mechanisms can be circumvented. It is our hope that with further refinement and optimization, incorporation of one
or more nigericins (or a related ionophore) into biologic drugs will eventually enable their use in
the treatment of diseases that are driven by intracellular targets.

**Materials and Methods**

**Preparation of Calcein Loaded Unilamellar Liposomes** - 20 mg of L-α-phosphatidylcholine (from egg), 8 mg of cholesterol and 2 mg of phosphatidylglycerol were dissolved in 2 mL of chloroform/methanol (2:1 v/v) in a 50 mL round bottom flask by slightly warming the contents (40-50 °C) until the lipids were miscible in the solvent. The solvent was then evaporated on a rotary evaporator under low pressure until a thin film of lipid was deposited on the walls of the flask. The residual solvent was evaporated under high vacuum for 1 h and 1 mL of 130 mM NaCl/20 mM Na₃PO₄ buffer (adjusted to pH 7 with HCl) containing 50 mM calcein dye (Sigma-Aldrich) was added to the flask. The lipid film was disrupted by stirring with magnetic glass beads at room temperature to yield a milky suspension of liposomes. Liposomes were then sonicated under N₂ for 10 min to prepare unilamellar liposomes. These liposomes were transferred to a high potassium buffer by passing through a PD MidiTrap G-25 column using an eluent mixture of 130 mM KCl and 20 mM K₃PO₄ buffer (adjusted to pH 7 with HCl). Liposomes were refrigerated (0-4 °C) until use.

**Characterization of the liposomes**: The liposome size and zeta-potential were measured using dynamic light scattering (Zetasizer Nano ZS, Malvern). Measurements were performed by dispersing liposomes in buffer (1:500) (130 mM KCl/20 mM K₃PO₄ buffer, pH 7.6). The temperature was set at 25 °C for all measurements. Three measurements were made per sample, and the averaged data was reported. The size of the liposomes were in the range of 400 ± 15 nm and charge of the liposome were −49.0 ± 1.6 mV.

**Cryo-TEM measurement**: The liposomes were applied to lacey carbon grids (Ultrathin Carbon Film on a Lace Carbon Support Film, 01824, Ted Pella) in 3 μL volume under ~90% relative humidity and double-blotted for 6 seconds. The liposome sample was flash frozen in liquid ethane using the semi-automated plunger Cp3 (Gatan). The flash-frozen sample was loaded on a CM200 transmission electron microscope under liquid nitrogen cryogenic conditions. The sample was screened at a nominal magnification of 50,000 X for the presence of liposomes. Micrographs were binned twice using ImageJ to better visualize liposomes (see Supporting Information, Fig. S15).
Assay of Calcein Release from Liposomes—10 µL of liposomes suspended in 1 mL of the 130 mM KCl and 20 mM K$_3$PO$_4$ buffer described above were placed in a transparent cuvette, with the addition of nigericin free acid or folate-nigericin conjugates at 100 nM in the presence of 20 mM DTT. The intensity of the absorption maximum was measured using a fluorescence spectrophotometer. Figure 2 presents a comparison of calcein dye release by various treatments of liposomes, including controls.

Relative Affinity Assay—FR-positive KB cells were gently trypsinized in 0.25% trypsin in phosphate-buffered saline (PBS) at room temperature and then diluted in folate-deficient RPMI medium (FDRPMI) containing 10% heat-inactivated fetal calf serum. After a 5-min 800g spin and one PBS wash, the final cell pellet was suspended in FDRPMI 1640 (no serum). Cells were incubated for 15 min on ice with 100 nmol/L of 3H-folic acid in the absence and presence of increasing concentrations of folate-nigericin. Samples were centrifuged at 10,000g for 5 min; cell pellets were suspended in buffer, transferred to individual vials containing 5 mL of scintillation cocktail, and then counted for radioactivity. Negative control tubes contained only the 3H-folic acid in FDRPMI (no competitor). Positive control tubes contained a final concentration of 1 mmol/L folic acid, and disintegrations per minute (dpm) measured in these samples (representing nonspecific binding of label) were subtracted from all samples. Notably, relative affinities were defined as the inverse molar ratio of compound required to displace 50% of 3H-folic acid bound to the FR on KB cells, and the relative affinity of folic acid for the FR was set to 1.

Determination of Nigericin Toxicity (IC$_{50}$). KB cells (100,000 cells/well) were seeded on amine-coated 24-well plates and allowed to form monolayers. After allowing the cells to reach ~60% confluence, spent medium was replaced with fresh medium and the desired concentrations of nigericin were added to each well. After incubating for 2 h at 37 °C, cells were rinsed 3× with fresh medium and then incubated an additional 66 h at 37 °C in fresh medium. Spent medium in each well was again replaced with fresh medium (0.5 mL) containing $^3$H-thymidine (1 µCi/ml), and the cells were incubated for an additional 4 h. After washing the cells 3× with medium, they were dissolved in 0.5 mL of 0.25 M NaOH. Thymidine incorporation was then determined by counting cell-associated radioactivity using a scintillation counter (Packard, Packard Instrument
Company). The IC$_{50}$ value was derived from a plot of the percent of $^3$H-thymidine incorporation versus log concentration using Graph Pad Prism 4 and TableCurve 2D software.

**Live cell proliferation assay**

KB cells were seeded in 96-well plates (Corning 3603; 2,000 cells/well) and incubated at 37 °C in 5% CO$_2$ overnight with 1% v/v NucLight Red Lentivirus (Essen Bioscience, Cat. No 4476). After replacement of the medium, different concentrations of the following reagents were then added to the wells: vehicle (DMSO), tubulysin, nigericin, and folate-nigericin. The plates were then placed in an IncuCyte S3 imaging instrument (Essen Bioscience), and each well was imaged every four hours for 24 hours using standard mode scan with a 10X objective and a red filter. Each assay concentration was replicated in three wells with five fields of view analyzed per well. Cell proliferation was quantified by counting the number of fluorescent nuclei over 24 hours using the IncuCyte S3 Software (Essen Bioscience). Data was exported and analyzed using Graphpad Prism v.7. Cell growth is represented as percent confluence as a function of time. To determine the concentration that resulted in 50% growth inhibition (IC$_{50}$), the 24-hour data points were graphed and normalized to vehicle treated control cells.

**Confocal Microscopy of Ionophore-Treated Cells**—Cells (100,000 cells/well in 0.5 mL culture medium) were seeded onto thin glass borosilicate Labtek™ 4-chambered dishes and incubated at 37 °C overnight to form a monolayer. On the following day, spent medium in each well was replaced with either fresh medium (well 1), fresh medium containing 10 nM folate-rhodamine conjugate 4 (well 2), or fresh medium containing either i) folate-nigericin ester conjugate 2 (100 nM) and folate-rhodamine conjugate 4 (10 nM); or ii) folate-nigericin amide conjugate 3 (100 nM) and folate-rhodamine conjugate 4 (10 nM); or iii) folate-nigericin ester conjugate 2 (200 nM) and Dy647 labeled methylated folate-siRNA (400 nM); or iv) folate carbamate nigericin conjugate 6 (30, 60 or 90 nM) and 10 nM folate-rhodamine conjugate 4. Treated cells were incubated for 1 h at 37°C before rinsing and replenishing with fresh medium (3 × 0.5 mL). The plated cells were then examined under an Olympus FV1000 Confocal Laser Scanning Microscope using a 60X oil-immersion objective over several hours (1-7 h) by excitation of either the rhodamine or Dylight 647 dyes. All fluorescence transmission images were obtained under identical conditions. The results section shows a representative sample out of all images collected.
**Cell Lines and Culture**—The FR-positive KB cell line was originally derived from a human nasopharyngeal epidermal carcinoma (33). KB cells used in this study had been maintained by the Cancer Cell Culture Facility in the Purdue University Department of Chemistry. It should be noted that KB cells purchased from the American Type Culture Collection are described as having the same origin but with the subsequent finding, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, that they were actually established via HeLa cell contamination. MDA-MB-231 cells were purchased from the American Type Culture Collection. MDA-MB-231 cells expressing high levels of FR were generated by passaging the cells for 14 weeks in folate-free cell culture medium. RAW264.7 cells is a murine macrophage-derived tumor cell line grown in folate-deficient medium. The cell lines were cultured in folate-deficient FDRPMI 1640 medium (Invitrogen, Grand Island, NY) supplemented with 10% heat inactivated fetal bovine serum (Sigma Aldrich, St. Louis, MO), penicillin (50 units/mL) and streptomycin (50µg/mL) and passaged continuously in a monolayer at 37°C in a humidified atmosphere containing 5% CO₂.

**Gene knockdown Assay** - The oligonucleotides were obtained from Integrated DNA Technologies, USA with the following modifications:

siLuc2 sense /5Phos/rGrGrArCrGrArCrGrArCrGrArCrGrArCrUmUmCrUrU; siLuc2 antisense /5AzideN/mGmArAmGrUrGmCrUmCrGmUrCmCrUmCrGmUCCrUrU (m: 2-O-methyl bases r: RNA bases). For siRNA targeting assays, MDA-MB-231 cells were seeded in 6 well plates at a density of 1x10⁶ cells/well and transfected with 2 µg of pmiRGlo plasmid (Promega) using Lipofectamine 2000 (Life Technologies). After 24 hours, cells were re-seeded into 96-well plates containing Fol-siLuc2, Fol-nigericin-siLuc2, Fol-NC (folate conjugated to non-targeting, negative control (NC) scrambled siRNA), Fol-nigericin-NC (folate conjugated to non-targeting, negative control (NC) scrambled siRNA) in folic acid and serum free RPMI medium for a final concentration of 50 nM. Untreated and unconjugated duplex siRNA were also included as controls. For each time point, Renilla and firefly luciferase values were obtained using the Dual Luciferase Reporter kit (Promega) following the manufacturer’s instructions. Firefly/Renilla ratios were normalized to Fol-NC or Fol-nigericin-NC for each time point. Experiments were performed three times with technical triplicates for each condition. Two-way analysis of variance (ANOVA) and Bonferroni post hoc test were used to test for statistical significance.
Acknowledgements

EC-119 (Pteroic acid-gGlu-Asp-Arg-Asp-Asp-Cys) was kindly donated by Endocyte, Inc. The folate-rhodamine conjugate 4 was donated by Dr. Sumith Kularatne (OnTarget Laboratories, LLC; Kurz Purdue Technology Center; 1281 Win Hentschel Blvd; West Lafayette, IN 47906). The Folate-siRNA-Dy647 conjugate was provided by Minnie Thomas, Department of Chemistry, Purdue University. The following shared resources of the Purdue University Center for Cancer Research (PCCR) were used to conduct the research reported in this paper: (1) Purdue University Interdepartmental NMR Facility; (2) Purdue University Flow Cytometry and Cell Sorting Facility. Funding for this research was provided by Endocyte Inc.

Supporting Information

Additional details of experimental procedures including synthesis and characterization data of synthesized compounds are provided in the Supporting Information file.

Competing interests

No competing interests declared by the authors.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DCC</td>
<td>N,N′-Dicyclohexylcarbodiimide</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>EC-119</td>
<td>(2R,5S,8S,11S,14S,19S)-19-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5,8,14-tris(carboxymethyl)-11-(3-guanidinopropyl)-2-(mercaptomethyl)-4,7,10,13,16-pentaaxo-3,6,9,12,15-pentaazaicosane-1,20-dioic acid</td>
</tr>
<tr>
<td>EtOAc</td>
<td>Ethyl Acetate</td>
</tr>
<tr>
<td>FDRPMI</td>
<td>Folate-Deficient RPMI (Roswell Park Memorial Institute) Medium</td>
</tr>
<tr>
<td>abbreviation</td>
<td>description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>FR</td>
<td>Folate Receptor</td>
</tr>
<tr>
<td>LC-MS</td>
<td>Liquid Chromatography-Mass Spectrometry</td>
</tr>
<tr>
<td>MeOH</td>
<td>Methanol</td>
</tr>
<tr>
<td>Proton Sponge®</td>
<td>Registered trademark for N, N, N’, N’-tetramethyl-1,8-naphthalenediamine</td>
</tr>
<tr>
<td>PyS-S(CH₂)₂OH</td>
<td>2-(pyridyldithio)-ethanol</td>
</tr>
<tr>
<td>RP-HPLC</td>
<td>Reversed-Phase High-Performance Liquid Chromatography</td>
</tr>
<tr>
<td>RT</td>
<td>Room Temperature</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin-Layer Chromatography</td>
</tr>
</tbody>
</table>

**References**


(43) http://sitem.herts.ac.uk/aeru/vsdb/Reports/2572.htm


